GTCR has completed its acquisition of Zentiva, a European generics pharmaceutical company, from Advent International. The Prague-based company serves more than 100 million people across over 40 countries with its portfolio of generic and specialty medicines. This transaction represents another strategic move by GTCR to expand its healthcare portfolio following previous investments in the sector.

Zentiva focuses on the development, manufacturing and supply of generic, branded specialty and over-the-counter medicines. The company's broad geographic footprint across Europe positions it well for continued growth in the generics market despite increasing competition. Advent International, which acquired Zentiva in 2018, is now exiting its investment after approximately five years of ownership.

Financial terms of the deal were not disclosed in the announcement. The acquisition comes as generic pharmaceutical companies face increasing competition from emerging markets and pricing pressures across Europe. GTCR's entry into the space suggests confidence in the long-term value of established generics manufacturers with established distribution networks and regulatory approvals.